Skip to main content
SpringerLink
Log in

Pharmacologic management of patients with both heart failure and diabetes

  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Diabetes and heart failure often occur together in patients, with each condition influencing the treatment of the other. Each disease has its own well-documented impact on prognosis, but when they are present in the same patient, the risk of morbidity and mortality increases substantially. Some therapies used in the treatment of diabetes are contraindicated in patients with heart failure, and some therapies for treating heart failure are often mistakenly believed to be contraindicated in patients with diabetes. This article aims to clarify the evidence behind treating these conditions simultaneously and dispel the myths surrounding the pharmacologic management of diabetes in heart failure and vice versa.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Wild S, Roglic G, Green A, et al.: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047–1053.

    Article  PubMed  Google Scholar 

  2. MacDonald MR, Petrie MC, Hawkins NM, et al.: Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 2008, 29:1224–1240.

    Article  PubMed  CAS  Google Scholar 

  3. MacDonald MR, Jhund PS, Petrie MC, et al.: Discordant short- and long-term outcomes associated with diabetes in patients with heart failure: importance of age and sex: a population study of 5.1 million people in Scotland. Circ Heart Fail 2008, 1:234–241.

    Article  Google Scholar 

  4. Masoudi FA, Inzucchi SE, Wang Y, et al.: Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005, 111:583–90.

    Article  PubMed  CAS  Google Scholar 

  5. Eurich DT, Majumdar SR, McAlister FA, et al.: Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005, 28:2345–2351.

    Article  PubMed  CAS  Google Scholar 

  6. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003, 163:2594–2602.

    Article  PubMed  Google Scholar 

  7. American Diabetes Association: Standards of medical care in diabetes—2008. Diabetes Care 2008, 31(Suppl 1):S12–S54.

    Article  Google Scholar 

  8. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457–2471. [Published erratum appears in N Engl J Med 2007, 357:100.]

    Article  PubMed  CAS  Google Scholar 

  9. Lago RM, Singh PP, Nesto RW: Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007, 370:1129–1136.

    Article  PubMed  CAS  Google Scholar 

  10. Dargie HJ, Hildebrandt PR, Riegger GA, et al.: A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol 2007, 49:1696–1704.

    Article  PubMed  CAS  Google Scholar 

  11. Giles TD, Miller AB, Elkayam U, et al.: Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail 2008, 14:445–452.

    Article  PubMed  CAS  Google Scholar 

  12. Eurich DT, McAlister FA, Blackburn DF, et al.: Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007, 335:497.

    Article  PubMed  CAS  Google Scholar 

  13. Nesto RW, Bell D, Bonow RO, et al.: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003, 108:2941–2948.

    Article  PubMed  Google Scholar 

  14. Smooke S, Horwich TB, Fonarow GC: Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 2005, 149:168–174.

    Article  PubMed  CAS  Google Scholar 

  15. Pocock SJ, Wang D, Pfeffer MA, et al.: Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2005, 27:65–75.

    Article  PubMed  Google Scholar 

  16. Nikolaidis LA, Elahi D, Hentosz T, et al.: Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004, 110:955–961.

    Article  PubMed  CAS  Google Scholar 

  17. Sokos GG, Nikolaidis LA, Mankad S, et al.: Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006, 12:694–699.

    Article  PubMed  CAS  Google Scholar 

  18. Duckworth W, Abraira C, Moritz T, et al.: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129–139.

    Article  PubMed  CAS  Google Scholar 

  19. Patel A, MacMahon S, Chalmers J, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560–2572.

    Article  PubMed  CAS  Google Scholar 

  20. Gerstein HC, Miller ME, Byington RP, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545–2559.

    Article  PubMed  CAS  Google Scholar 

  21. US Food and Drug Administration: Guidance for Industry Diabetes Mellitus: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. Available at http://www.fda.gov/CDER/guidance/8576fnl.pdf. Accessed on April 21, 2009.

  22. Taylor AL, Ziesche S, Yancy CW, et al.: Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. Circulation 2007, 115:1747–1753.

    Article  PubMed  CAS  Google Scholar 

  23. Shekelle PG, Rich MW, Morton SC, et al.: Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003, 41:1529–1538.

    Article  PubMed  CAS  Google Scholar 

  24. Young JB, Dunlap ME, Pfeffer MA, et al.: Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004, 110:2618–2626.

    Article  PubMed  CAS  Google Scholar 

  25. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675.

    Article  PubMed  CAS  Google Scholar 

  26. Fernandez HM, Leipzig RM: Spironolactone in patients with heart failure. N Engl J Med 2000, 342:132–134.

    Article  PubMed  CAS  Google Scholar 

  27. O’Keefe JH, Abuissa H, Pitt B: Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes Obes Metab 2008, 10:492–497.

    Article  PubMed  Google Scholar 

  28. Wlodarczyk JH, Keogh A, Smith K, McCosker C: CHART: congestive cardiac failure in hospitals, an Australian review of treatment. Heart Lung Circ 2003, 12:94–102.

    Article  PubMed  Google Scholar 

  29. Erdmann E, Lechat P, Verkenne P, Wiemann H: Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001, 3:469–479.

    Article  PubMed  CAS  Google Scholar 

  30. Bristow MR, Gilbert EM, Abraham WT, et al.: Effect of carvedilol on LV function and mortality in diabetic versus non-diabetic patients with ischemic or nonischemic dilated cardiomyopathy [abstract]. Circulation 1996, 94:I–664.

    Google Scholar 

  31. Mohacsi P, Fowler MB, Krum H, et al.: Should physicians avoid the use of beta-blockers in patients with heart failure who have diabetes? Results of the COPERNICUS study [abstract 3551]. Circulation 2001, 104:II–754.

    Google Scholar 

  32. Deedwania PC, Giles TD, Klibaner M, et al.: Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005, 149:159–167.

    Article  PubMed  CAS  Google Scholar 

  33. Haas SJ, Vos T, Gilbert RE, Krum H: Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003, 146:848–853.

    Article  PubMed  CAS  Google Scholar 

  34. Shorr RI, Ray WA, Daugherty JR, Griffin MR: Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997, 278:40–43.

    Article  PubMed  CAS  Google Scholar 

  35. Herings RM, de Boer A, Stricker BH, et al.: Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995, 345:1195–1198.

    Article  PubMed  CAS  Google Scholar 

  36. Morris AD, Boyle DI, McMahon AD, et al.: ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes. DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside, Scotland. Medicines Monitoring Unit. Diabetes Care 1997, 20:1363–1367.

    Article  PubMed  CAS  Google Scholar 

  37. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 [no authors listed]. BMJ 1998, 317:713–720.

  38. Sawicki PT, Siebenhofer A: Betablocker treatment in diabetes mellitus. J Intern Med 2001, 250:11–17.

    Article  PubMed  CAS  Google Scholar 

  39. Giugliano D, Acampora R, Marfella R, et al.: Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med 1997, 126:955–959.

    PubMed  CAS  Google Scholar 

  40. Popp DA, Tse TF, Shah SD, et al.: Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus. Diabetes Care 1984, 7:243–247.

    Article  PubMed  CAS  Google Scholar 

  41. Komajda M, Lutiger B, Madeira H, et al.: Tolerability of carvedilol and ACE-inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF Evaluation). Eur J Heart Fail 2004, 6:467–475.

    Article  PubMed  CAS  Google Scholar 

  42. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions [no authors listed]. N Engl J Med 1992, 327:685–691. [Published erratum appears in N Engl J Med 1992, 327:1768.]

  43. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease [no authors listed]. Lancet 1997, 349:375–380.

  44. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) [no authors listed]. N Engl J Med 1987, 316:1429–1435.

  45. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709–717.

    Article  PubMed  CAS  Google Scholar 

  46. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) [no authors listed]. Lancet 1999, 353:2001–2007.

  47. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators [no authors listed]. N Engl J Med 1991, 325:293–302.

  48. Granger CB, McMurray JJ, Yusuf S, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772–776.

    Article  PubMed  CAS  Google Scholar 

  49. The effect of digoxin on mortality and morbidity in patients with heart failure [no authors listed]. N Engl J Med 1997, 336:525–533.

  50. McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767–771.

    Article  PubMed  CAS  Google Scholar 

  51. Taylor AL, Ziesche S, Yancy C, et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049–2057. [Published erratum appears in N Engl J Med 2005, 352:1276.]

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Hairmyres Hospital, Eaglesham Road, East Kilbride, Glasgow, G75 8RG, Scotland, UK

    Michael R. MacDonald

Authors
  1. Michael R. MacDonald
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark C. Petrie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miles Fisher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John J. V. McMurray
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael R. MacDonald.

Rights and permissions

Reprints and permissions

About this article

Cite this article

MacDonald, M.R., Petrie, M.C., Fisher, M. et al. Pharmacologic management of patients with both heart failure and diabetes. Curr Heart Fail Rep 6, 126–132 (2009). https://doi.org/10.1007/s11897-009-0019-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-009-0019-3

Keywords

Search

Navigation